Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

Jordi Bruix, Won-Young Tak, Antonio Gasbarrini, Armando Santoro, Massimo Colombo, Ho-Yeong Lim, Vincenzo Mazzaferro, Reiner Wiest, María Reig, Andrea Wagner, Luigi Bolondi

Research output: Contribution to journal › Article

154 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science